Functional imaging in thyroid cancer patients with metastases and therapeutic implications

xlomafota13 shared this article with you from Inoreader Functional imaging in thyroid cancer patients with metastases and therapeutic implications Via radioactive iodine Presse Med. 2022 Feb 4:104113. doi: 10.1016/j.lpm.2022.104113. Online ahead of print. ABSTRACT Functional imaging plays a central role in the management of thyroid cancer patients. In patients with a differentiated thyroid cancer (DTC), radioactive iodine (RAI) is used mostly with a therapeutic intent, either post-operatively or as the first line systemic treatment in patients with known structural disease. A whole body scan is performed a few days after the RAI administration, and this procedure is very sensitive to detect all tumor foci with RAI uptake. PET/CT with 18F-FDG complements the use of RAI at the initial evaluation of patients with high-risk DTC, during follow-up in those with rising serum thyroglobulin levels over time, for the work-up of patients with documented structural disease and for assessing the efficacy of focal or systemic treatment modalities. 18F-FDG uptake is a prognostic indicator in all these clinical conditions. A dosimetric approach with 124I PET/CT showed encouraging results. Several functional imaging modalities are currently available for medullary thyroid carcinoma (MTC) patients. 18F-FDG-PET/CT may be sensitive in MTC patients with high FDG uptake that signals aggressive disease. 18F-DOPA is the most sensitive imaging technique to visualize small tumor foci, and is also highly specific in patients with a known MTC, but should be complemented by a CT scan of the chest and by a MRI of the liver to detect small metastases. PMID:35131318 | DOI:10.1016/j.lpm.2022.104113 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.